Park Meditech gets $10 million infusion

Article

Park Meditech of Lachine, Quebec, the parent company of gammacamera vendor Park Medical, has signed a deal with a Canadiancapital development fund for a private placement worth up to $10million in funds for Park. The fund, Fonds de solidarite des

Park Meditech of Lachine, Quebec, the parent company of gammacamera vendor Park Medical, has signed a deal with a Canadiancapital development fund for a private placement worth up to $10million in funds for Park. The fund, Fonds de solidarite des travailleursdu Quebec (the Fonds), agreed to purchase debentures and commonstock issued by Park.

As part of the deal, Park investors Pinetree Capital and Analogichave agreed to convert debt owed to them by Park into notes andcommon stock. Once the debentures are converted and the deal finalized,the Fonds could own up to 12.5 million shares of Park stock, representing27% of shares outstanding, and would be Park's largest shareholder.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.